Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.52 |
| ▸ | PSEN1 | P49768 | 9/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 9/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 9/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 9/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 9/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 9/20 | 0.52 |
| ▸ | PORCN | Q9H237 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1492889 | 1.00 | ROCK2 (0.52) | ROCK2ROCK1PSEN1PSEN2APH1B | |
| SCHEMBL8009322 | 0.87 | PSEN1 (0.68) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2181897 | 0.87 | PSEN1 (0.68) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1492754 | 0.85 | PSEN1 (0.65) | ROCK2ROCK1PSEN1PSEN2APH1B | |
| SCHEMBL1492672 | 0.84 | PSEN1 (0.53) | ROCK2ROCK1PSEN1PSEN2APH1B | |
| SCHEMBL7964847 | 0.84 | PSEN1 (0.53) | ROCK2ROCK1PSEN1PSEN2APH1B | |
| SCHEMBL12650367 | 0.83 | ROCK2 (0.74) | ROCK2ROCK1PSEN1PSEN2APH1B | |
| SCHEMBL1492958 | 0.83 | ROCK2 (0.74) | ROCK2ROCK1PSEN1PSEN2APH1B | |
| SCHEMBL27809653 | 0.83 | ROCK2 (0.74) | ROCK2ROCK1PSEN1PSEN2APH1B | |
| SCHEMBL1492659 | 0.83 | PSEN1 (0.58) | ROCK2ROCK1PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | ROCK2 4585/4885ROCK1 4259/4885PSEN1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.